Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
Primary Purpose
Pain, Osteoarthritis
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Placebo
Buprenorphine Transdermal System
Sponsored by

About this trial
This is an interventional treatment trial for Pain focused on measuring Osteoarthritic Pain
Eligibility Criteria
Inclusion Criteria: Males or females ages 40 years or older. Clinical diagnosis of osteoarthritis (OA) of the hip or knee. Exclusion Criteria: Subjects who have a current or past history of chronic disease(s), in addition to OA, requiring frequent analgesic therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, low back pain, and diabetic neuropathy).
Sites / Locations
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
- Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
0
1
Arm Description
Outcomes
Primary Outcome Measures
The time to the development of inadequate analgesia
Secondary Outcome Measures
Percentage of subjects who developed inadequate analgesia, 'Average pain over the last 24 hours' scores
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00345787
Brief Title
Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
Official Title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Osteoarthritic Pain of the Hip or Knee
Study Type
Interventional
2. Study Status
Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
August 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Mundipharma K.K.
4. Oversight
5. Study Description
Brief Summary
The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.
Detailed Description
The primary objective of this study is to evaluate the efficacy and safety of buprenorphine transdermal system (BTDS) compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee who have a sub-optimal response to their non-opioid analgesic treatment and require opioid analgesics for pain control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Osteoarthritis
Keywords
Osteoarthritic Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
262 (Actual)
8. Arms, Groups, and Interventions
Arm Title
0
Arm Type
Placebo Comparator
Arm Title
1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Corresponding placebo is applied for 12weeks
Intervention Type
Drug
Intervention Name(s)
Buprenorphine Transdermal System
Intervention Description
Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
Primary Outcome Measure Information:
Title
The time to the development of inadequate analgesia
Time Frame
Up to 12weeks
Secondary Outcome Measure Information:
Title
Percentage of subjects who developed inadequate analgesia, 'Average pain over the last 24 hours' scores
Time Frame
12weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females ages 40 years or older.
Clinical diagnosis of osteoarthritis (OA) of the hip or knee.
Exclusion Criteria:
Subjects who have a current or past history of chronic disease(s), in addition to OA, requiring frequent analgesic therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, low back pain, and diabetic neuropathy).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mutsukuni Kataoka
Organizational Affiliation
Department Head, Clinical Trial Operations, Clinical Development, Mundipharma K.K.
Official's Role
Study Chair
Facility Information:
Facility Name
Investigational Site
City
Nagoya
State/Province
Aichi
Country
Japan
Facility Name
Investigational Site
City
Okazaki
State/Province
Aichi
Country
Japan
Facility Name
Investigational Site
City
Ichikawa
State/Province
Chiba
Country
Japan
Facility Name
Investigational Site
City
Matsudo
State/Province
Chiba
Country
Japan
Facility Name
Investigational Site
City
Nagareyama
State/Province
Chiba
Country
Japan
Facility Name
Investigational Site
City
Annaka
State/Province
Gunma
Country
Japan
Facility Name
Investigational Site
City
Takasaki
State/Province
Gunma
Country
Japan
Facility Name
Investigational Site
City
Chitose
State/Province
Hokkaido
Country
Japan
Facility Name
Investigational Site
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Investigational Site
City
Kako
State/Province
Hyogo
Country
Japan
Facility Name
Investigational Site
City
Kobe
State/Province
Hyogo
Country
Japan
Facility Name
Investigational Site
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Investigational Site
City
Joyo
State/Province
Kyoto
Country
Japan
Facility Name
Investigational Site
City
Sendai
State/Province
Miyagi
Country
Japan
Facility Name
Investigational Site
City
Isahaya
State/Province
Nagasaki
Country
Japan
Facility Name
Investigational Site
City
Kasukabe
State/Province
Saitama
Country
Japan
Facility Name
Investigational Site
City
Koshigaya
State/Province
Saitama
Country
Japan
Facility Name
Investigational Site
City
Hikone
State/Province
Shiga
Country
Japan
Facility Name
Investigational Site
City
Adachi
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Arakawa
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Edogawa
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Koto
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Setagaya
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Suginami
State/Province
Tokyo
Country
Japan
Facility Name
Investigational Site
City
Himi
State/Province
Toyama
Country
Japan
Facility Name
Investigational Site
City
Kurobe
State/Province
Toyama
Country
Japan
Facility Name
Investigational Site
City
Fukui
Country
Japan
Facility Name
Investigational Site
City
Osaka
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
We'll reach out to this number within 24 hrs